Affimed NV (Affimed NV) LT-Debt-to-Total-Asset : 0.13 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Affimed NV LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Affimed NV's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.13.

Affimed NV's long-term debt to total assets ratio increased from Dec. 2022 (0.06) to Dec. 2023 (0.13). It may suggest that Affimed NV is progressively becoming more dependent on debt to grow their business.

Affimed NV LT-Debt-to-Total-Asset Historical Data

The historical data trend for Affimed NV's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affimed NV LT-Debt-to-Total-Asset Chart

Affimed NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.08

0.06

0.13

Affimed NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.06	0.06	0.07	0.12	0.13

Affimed NV LT-Debt-to-Total-Asset Calculation

Affimed NV's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	14.154	/	105.951
	=	0.13

Affimed NV's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	14.154	/	105.951
	=	0.13

Affimed NV (NAS:AFMD) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Affimed NV LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Affimed NV's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Affimed NV (Affimed NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (NAS:AFMD) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

A28:Germany

Address

Im Neuenheimer Feld 582, Technologiepark, Heidelberg, BW, DEU, 69120

Website

https://www.affimed.com

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.